Cardiff Oncology (CRDF) Liabilities and Shareholders Equity (2016 - 2025)
Historic Liabilities and Shareholders Equity for Cardiff Oncology (CRDF) over the last 16 years, with Q3 2025 value amounting to $63.8 million.
- Cardiff Oncology's Liabilities and Shareholders Equity rose 140.55% to $63.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $321.5 million, marking a year-over-year increase of 1296.25%. This contributed to the annual value of $97.2 million for FY2024, which is 1905.14% up from last year.
- According to the latest figures from Q3 2025, Cardiff Oncology's Liabilities and Shareholders Equity is $63.8 million, which was up 140.55% from $75.7 million recorded in Q2 2025.
- Cardiff Oncology's Liabilities and Shareholders Equity's 5-year high stood at $149.5 million during Q4 2021, with a 5-year trough of $62.9 million in Q3 2024.
- In the last 5 years, Cardiff Oncology's Liabilities and Shareholders Equity had a median value of $97.5 million in 2023 and averaged $103.8 million.
- As far as peak fluctuations go, Cardiff Oncology's Liabilities and Shareholders Equity soared by 99664.48% in 2021, and later plummeted by 3222.41% in 2024.
- Quarter analysis of 5 years shows Cardiff Oncology's Liabilities and Shareholders Equity stood at $149.5 million in 2021, then dropped by 22.3% to $116.2 million in 2022, then fell by 29.74% to $81.6 million in 2023, then increased by 19.05% to $97.2 million in 2024, then crashed by 34.38% to $63.8 million in 2025.
- Its last three reported values are $63.8 million in Q3 2025, $75.7 million for Q2 2025, and $84.8 million during Q1 2025.